Quench Bio

Quench Bio is a biotechnology company leveraging new insights into gastrin biology and innate immunity to develop drugs for severe inflammatory diseases. The lead compound in Quench Bio’s pipeline targets and inhibits the pore-forming protein Gasdermin D (a key molecule in the pyroptosis and NETosis pathways), which mediates the release of inflammatory cytokines, alarmins, DNA, and NETs.